European Study of Prostate Cancer Screening — 23-Year Follow-up

Author(s): Monique J. Roobol, Ph.D.¹; Ivo I. de Vos, M.D.¹; Marianne Månsson, Ph.D.²; Rebecka A. Godtman, M.D., Ph.D.²; Kirsi M. Talala, Ph.D.³; Elly den Hond, Ph.D.⁴; Vera Nelen, M.D., Ph.D.⁴; Arnauld Villers, M.D., Ph.D.⁵; Gregoire Poinas, M.D.⁶; Maciej Kwiatkowski, M.D., Ph.D.^7,8,9; Stephen Wyler, Ph.D., M.D.^7,8; Franz Recker, M.D., Ph.D.⁷; Donella Puliti, Ph.D.¹⁰; Giuseppe Gorini, M.D., Ph.D.¹⁰; Marco Zappa, Ph.D.¹⁰; Alvaro Paez, M.D.¹¹; Marcos Lujan, M.D.¹²; Chris H. Bangma, M.D., Ph.D.¹; Teuvo Tammela, M.D., Ph.D.^13,14; Fritz H. Schröder, M.D., Ph.D.¹; Sebastiaan Remmers, Ph.D.¹; Jonas Hugosson, M.D., Ph.D.²; Anssi Auvinen, M.D., Ph.D.¹⁵; the ERSPC Investigators*;

Source: DOI: 10.1056/NEJMoa2503223

Dr. Maen Hussein's Thoughts

A 13% reduction in mortality was observed in the screening group, with an improved harm-benefit ratio. For every 456 men screened, one prostate cancer death was prevented. It is an easy and inexpensive test, though concerns remain regarding unnecessary biopsies and overtreatment.

BACKGROUND

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.

METHODS

We updated the findings from ERSPC, a multicenter, randomized study conducted across eight European countries with a focus on a predefined core age group of 162,236 men who were 55 to 69 years of age the time of randomization. Participants were randomly assigned to the screening group and offered repeated PSA testing or to the control group and not invited for screening. The primary outcome was prostate cancer mortality. Research Summary European Study of Prostate Cancer Screening — 23-Year Follow-up

RESULTS

After a median follow-up of 23 years, prostate cancer mortality was 13% lower in the screening group (rate ratio, 0.87; 95% confidence interval [CI], 0.80 to 0.95), and the absolute risk reduction was 0.22% (95% CI, 0.10 to 0.34). The cumulative incidence of prostate cancer was higher in the screening group than in the control group (rate ratio, 1.30; 95% CI, 1.26 to 1.33). a median of 23 years of follow-up, one death from prostate cancer was prevented for every 456 men (95% CI, 306 to 943) who were invited for screening, and one death from prostate cancer was averted for every 12 men (95% CI, 8 to 26) in whom prostate cancer was diagnosed, as compared with one death from prostate cancer prevented for every 628 men (95% CI, 419 to 1481) and one death averted for every 18 men (95% CI, 12 to 45) 16 years of follow-up.

CONCLUSIONS

Long-term follow-up confirms a sustained reduction in deaths from prostate cancer with PSA testing, alongside an improved harm–benefit ratio. Future screening strategies should adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits. (Funded by the Dutch Cancer Society and others; ERSPC ISRCTN registry number, ISRCTN49127736.)

Author Affiliations

¹Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands; ²Department of Urology, Sahlgrenska Academy Goteborg University, Gothenburg, Sweden; ³Cancer Society of Finland, Helsinki; ⁴Provincial Institute for Hygiene, Antwerp, Belgium; ⁵Department of Urology, Lille, Universite Lille Nord de France, Lille, France; ⁶Department of Urology, Clinique Beau Soleil, Montpellier, France; ⁷Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland; ⁸Member of Medical Faculty, University of Basel, Basel, Switzerland; ⁹Department of Urology, Academic Hospital Braunschweig, Braunschweig, Germany; ¹⁰Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy; ¹¹Department of Urology, Hospital Universitario de Fuenlabrada, Madrid; ¹²Department of Urology, Hospital Universitario Infanta Cristina, Madrid; ¹³Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ¹⁴Department of Urology, Tampere University Hospital, Tampere, Finland; ¹⁵Prostate Cancer Research Center, Faculty of Social Sciences, Tampere University, Tampere, Finland

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Metformin did not significantly reduce the risk of disease progression compared with active surveillance in patients with low-risk prostate cancer.

177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

For our radiation oncology colleagues, the addition of PSMA-directed therapy prior to stereotactic body radiation therapy (SBRT) improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Two cycles of PSMA-directed therapy were administered before SBRT.

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Pasritamig was administered to patients who had received a median of four prior lines of systemic therapy. It was well tolerated, with manageable adverse events, making it suitable for outpatient administration. The treatment showed a median radiographic progression-free survival of 7.85 months, and 14 out of 33 participants achieved a ≥50% reduction in baseline PSA levels. So, stay tuned.

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial

In patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease, the long-term update reveals 13-year outcomes. Treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT.